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Abstract
Background: Governments aim to increase treatment participation by problematic drug users. In
the UK this has been achieved by fiscal investment, an expanded workforce, reduced waiting times
and coercive measures (usually criminal justice (CJ) led). No assessment of these measures on
treatment outcomes has been made. Using established monitoring systems we assessed trends in
'dropped out' and 'discharged drug free' (DDF), since the launch of the national drug strategy, and
rates of treatment re-presentation for these cohorts.
Methods: A longitudinal dataset of drug users (1997 to 2004/05, n = 26,415) was used to identify
people who dropped out of, and were DDF from, services for years 1998 to 2001/02, and re-
presentations of these people in years to 2004/05. Trends in drop out and DDF, baseline
comparisons of those DDF and those who dropped out and outcome comparisons for those
referred from the CJ system versus other routes of referral were examined using chi square.
Logistic regression analyses identified variables predicting drop out versus DDF and subsequent re-
presentation versus no re-presentation.
Results: The proportion of individuals dropping out has increased from 7.2% in 1998 to 9.6% in
2001/02 (P < 0.001). The proportion DDF has fallen from 5.8% to 3.5% (P < 0.001). Drop out was
more likely in later years, by those of younger age and by CJ referrals. The proportion re-presenting
to treatment in the following year increased from 27.8% in 1998 to 44.5% in 2001/02 (P < 0.001)
for those DDF, and from 22.9% to 48.6% (P < 0.001) for those who dropped out. Older age and
prior treatment experience predicted re-presentation. Outcome (drop out or DDF) did not
predict re-presentation.
Conclusion: Increasing numbers in treatment is associated with an increased proportion dropping
out and an ever-smaller proportion DDF. Rates of drop out are significantly higher for those
coerced into treatment via the CJ system. Rates of re-presentation are similar for those dropping
out and those DDF. Encouragingly, those who need to re-engage with treatment, particularly those
who drop out, are doing so more quickly. The impact of coercion on treatment outcomes and the
appropriateness of aftercare provision require further consideration.
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Background
In many countries the health, social and criminal justice
consequences of problematic drug use create an economic
burden estimated at between 0.5% and 1.3% of gross
domestic product [1]. Providing drug treatment pro-
grammes for drug users is considered both a cost effective
and humanitarian response [2]. In the UK, treatment is
seen as the cornerstone for tackling problematic drug use
and increasing the number of drug users in structured
treatment continues to be a key aim of the national drug
strategy [3].
Internationally, governments employ diverse methods to
attract drug users into treatment. Across a range of devel-
oping countries (as an example Thailand [4]), and
increasingly throughout the developed world, recruitment
into treatment is being achieved through compulsory or
quasi-compulsory drug treatment orders issued through
the criminal justice system [5]. In the United States, for
example, drug courts are solely used to divert drug-using
offenders away from prison into programmes involving
drug testing, treatment, supervision and court-mandated
sanctions for non-compliance. The number of drug courts
has increased dramatically in the US since the mid 1990s
[6], with other countries subsequently adopting similar
models [7,8].
In the UK, a number of programmes have been initiated
since the launch of the national drug strategy in 1998 to
increase the number of drug users accessing treatment.
Initially, massive additional funding expanded treatment
provision and consequently reduced treatment waiting
times. Secondly, in recognition of increasing crack use
within the UK, the link between crack use and (violent)
crime and the reliance in the UK on traditional substitute
opiate prescribing services, specific treatment services for
stimulant users were established [9]. These measures have
been supplemented by a number of systems to encourage
drug-using offenders to participate in treatment. Drug
Treatment and Testing Orders (DTTOs), criminal justice
led abstinence-focused interventions managed by the Pro-
bation Service, were introduced in 2000. The same year
saw the launch of England's Arrest Referral initiative, a
scheme which placed drugs workers in custody suites to
ask arrestees about their drug use and to refer those who
admitted use to treatment providers [10]. Although partic-
ipants in Arrest Referral might receive lesser sentences for
entering treatment, more recent interventions have even
greater coercive elements with lesser judicial penalties in
return for treatment compliance [11].
In 2003 the plethora of criminal justice based initiatives
were integrated into one overarching strategy, the Drug
Interventions Programme (DIP), which annually receives
approximately £165 million of funding [12]. In combina-
tion, these initiatives, both criminal justice orientated and
otherwise, have successfully increased the number of peo-
ple accessing treatment services [13]. However, the effects
of rises in recruitment of users into drug services (coercive
and otherwise) on outcomes, particularly on retention in
treatment, is of increasing importance but remains poorly
understood.
Cheshire and Merseyside (population 2,345,077; 4.7% of
England) is a mixed rural and urban area in the North
West of England with prevalence of problematic drug use
(usually opiate and crack addiction) as high as 52 per
1,000 male population aged 15 to 44 years in some areas
[14]. In 2004/05, 8% of all clients of structured drug treat-
ment services within England were resident within the
Cheshire and Merseyside area [15]. It is the only area of
the UK that has consistently collected treatment outcome
data on all clients of drug services annually since 1996
(data for 1996 are not typically reported as the system was
being developed in situ this year). Therefore, it provides a
unique opportunity to evaluate changes in both treatment
outcomes for those in structured services and trends in
overall retention during a period of major changes in drug
services.
Here we consider two outcomes; 'discharged drug free',
(defined as a planned discharge from treatment following
cessation of drug use and treatment completion), and
'drop out', (defined as unplanned discharge from services
before treatment completion). Using data from the mon-
itoring system we test two hypotheses: firstly that meas-
ures designed to increase numbers in treatment have led
to an increase in proportions dropping out of treatment
and secondly, that the proportion of people discharged
drug free has shown a converse trend during the same
time period. We compare the characteristics of those drop-
ping out of treatment and those discharged drug free and
consider what factors predict their re-presentation at treat-
ment in the subsequent year. Further, we test the hypoth-
esis that the rate of re-presentation to treatment is greater
for those who drop out of treatment than for those dis-
charged drug free. Finally, for a limited group of people,
we explore the relationship between referral source, crim-
inal justice or otherwise, and treatment outcome (drop
out or drug free discharge). Here we hypothesise that drop
out from treatment is more common amongst those
referred into treatment via the criminal justice system
than through other referral sources, due to the coercive
nature of criminal justice initiatives, and that drug free
discharge is more common for those referred from non-
criminal justice sources.
Methods
In 1996, on behalf of the local health services, the Centre
for Public Health established a monitoring system to
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record details of all clients at structured drug treatment
services in Cheshire and Merseyside. In addition to mon-
itoring prevalence, agency staff were asked to provide out-
come data, on a six-monthly basis (1st January to 30th
June; 1st July to 31st December), for each client they treated
(outcomes included; 'in contact with treatment', 'lost to
prison', 'discharged drug free', 'referred to another agency',
'known dead', 'dropped out of treatment' and 'not in con-
tact with treatment, other reason' [16]). At this time the
national system for monitoring drug treatment contacts
was not collecting prevalence and outcome data. How-
ever, a new National Drug Treatment Monitoring System
(NDTMS), based largely on the Cheshire and Merseyside
system was introduced in 2001 [14] and this began col-
lecting prevalence and outcome data on an annual cycle
(1st April to 31st March). Thus from April 2001 the system
for Cheshire and Merseyside was integrated into the
NDTMS and consequently its reporting period changed.
Both systems collected data on those individuals in 'struc-
tured treatment services', primarily consisting of substi-
tute prescribing, structured counselling and abstinence
based services but excluding low threshold services such
as needle exchange and drop in services (for a full expla-
nation of the treatment tiers see Models of Care for Sub-
stance Misusers [17]).
Both the Cheshire and Merseyside system and the NDTMS
collect data in a pseudo-anonymous form, with each indi-
vidual being identified by their attributor code, comprised
of their initials, date of birth and sex. The use of this attrib-
utor code for data matching and duplicate removal was
validated and can be used to anonymously track individ-
uals across years. Both systems recorded outcome data for
each individual at every agency. Whilst the NDTMS
records more detailed outcome data than the system it
replaced, definitions for 'drug free discharge' and 'drop
out' are consistent across the systems. Due to the similar-
ities between the two systems, data have been amalga-
mated into a single longitudinal dataset comprising of
26,415 individuals contacting treatment services between
1st January 1997 and 31st March 2005 (aged 11 to 74).
This longitudinal dataset was used to retrospectively iden-
tify end of year treatment outcomes for each individual, in
annual cohorts for years 1998 to 2001/02 (1998 repre-
sented the launch of the UK Drug Strategy, and 2001/02
was chosen as a cut off to enable three years of re-presen-
tation data to accrue). Individuals reported as having end
of year outcomes of drug free discharge and drop out were
identified for the years 1998 to 2001/02. The data set was
used to extract their attributor code, age (at the end of
each reporting period), gender and information on prior
treatment naivety/experience (defined here as no treat-
ment contact from 1997/at least one prior treatment con-
tact from 1997 to each year they appear in the dataset).
Within year baseline comparisons between all treatment
clients that were discharged drug free and those that
dropped out of treatment were made by gender, age group
and prior treatment naivety/experience using chi squared
analyses. Backwards, stepwise binary logistic regression
was used to identify variables which predicted drop out
(compared to drug free discharge) and variables which
predicted re-presentation (compared to no re-presenta-
tion) at structured treatment the year following drop out
or drug free discharge irrespective of referral source. The
Hosmer and Lemeshow test was used to assess the good-
ness of fit of the regression models [18]. Significance was
set at P < 0.05 for logistic regression analyses. The longitu-
dinal dataset was used to calculate rates of re-presentation
in the year following drop out and drug free discharge up
to the year 2004/05. Chi squared for trend was used for
three analyses: firstly to assess changes in the proportion
of individuals dropping out of treatment each year for the
years 1998 to 2001/02; secondly to assess changes in the
proportion of individuals discharged drug free each year
during the same period of time; and finally, to assess
trends in the proportion of people re-presenting at treat-
ment in the following year (following drug free discharge
and drop out). Logistic regression analyses were under-
taken using SPSS v12 software [19]. All chi squared tests
were performed using EpiInfo v6 [20].
Finally, this longitudinal dataset was used to retrospec-
tively identify episodic treatment outcomes for those
referred via the criminal justice system (mainly the Proba-
tion Service, Prison Officers, the Police, the Bail Support
Scheme, Arrest Referral, Youth Offending Teams, Drug
Treatment and Testing Orders and the court system) and
those referred from other sources (mainly self referrals, or
referrals through a General Practitioner or a drug service),
in annual cohorts for 1998 to 2001/02. Outcomes for all
treatment episodes and new treatment episodes (defined
here as treatment episodes of people not recorded in treat-
ment the previous year) were analysed separately. Chi
squared analysis was used to assess differences in drop out
and drug free discharge between those referred by the
criminal justice system and those referred via other
sources using EpiInfo v6 [20].
Ethical approval was not sought for this study which
relied on the use of routinely collected, pseudo-anony-
mous monitoring data.
Results
The total number of individuals (aged 11 to 74 years) in
contact with treatment services in Cheshire and Mersey-
side was 7594, 7261, 8166 and 8061 for the years 1998 to
2001/02 respectively. Across all years, an end of year treat-
ment outcome was available for 71% of records. The pro-
portion of individuals who dropped out of treatment
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significantly increased from 7.2% in 1998, through 6.8%
in 1999 and 8.3% in 2000/01 to 9.6% in 2001/02 (X2
trend = 22.30, P < 0.001). Conversely, the proportion of
people discharged drug free significantly decreased as fol-
lows: 1998, 5.8%; 1999, 9.9%; 2000/01, 4.4%; 2001/02,
3.5% (X2 trend = 128.45, P < 0.001).
Within year comparisons showed that gender, age group
and prior treatment contact was not significantly related
to whether individuals were discharged drug free or
dropped out (Table 1). Across years, logistic regression
analysis showed drop out was predicted by younger age
and year of treatment contact. Overall people were more
likely to drop out in later years (after 1998; Table 2) with
the exception of 1999 when the numbers recorded in
treatment actually fell slightly.
The proportion of those discharged drug free who then re-
presented to treatment services in the following year sig-
nificantly increased as follows; 1998, 27.8%; 1999,
33.6%; 2000/01, 26.9%, 2001/02, 44.5% (X2 trend =
11.78, P < 0.001). Similarly, the proportion of those who
dropped out of treatment and then re-presented in the
subsequent year increased as follows; 1998, 22.9%; 1999,
26.3%; 2000/01, 31.8%; 2001/02, 48.6% (X2 trend =
103.31, P < 0.001). Figure 1 shows cumulative rates of re-
presentation to treatment services following drug free dis-
charge and drop out for each year cohort from 1998 to
2001/02. Thus, of those discharged drug free in 1998,
57.1% had re-presented at treatment services in at least
one subsequent year by 2004/05, and of those who
dropped out in 1998, the equivalent proportion re-pre-
senting by 2004/05 was 53.8%
Re-presentation to treatment in the year following treat-
ment disengagement (of those discharged drug free and
those who dropped out of treatment) was predicted by
older age, having had previous treatment contact (i.e.
those that were new to treatment when they dropped out
were less likely to re-present) and year of treatment con-
tact; people were more likely to re-present if discharged
drug free or dropped out of treatment in 2000/01 or later
than in previous years (Table 3). There was no significant
difference in the rate of re-presentation, the year following
Table 2: Factors predicting drop out from drug treatment 
compared to drug free discharge
Factors predicting drop out from treatment (N = 4291)
Variable Adjusted odds ratio (95% confidence interval) P value
Age group 0.013
10 to 19 Ref
20 to 29 0.62 (0.45, 0.86) 0.003
30 to 39 0.68 (0.49, 0.93) 0.016
40 to 49 0.55 (0.37, 0.81) 0.003
50 to 59 0.43 (0.24, 0.76) 0.004
60 to 69 0.23 (0.02, 2.74) 0.245
Year < 0.001
1998 Ref
1999 0.55 (0.46, 0.66) < 0.001
2000/01* 1.53 (1.28, 1.83) < 0.001
2001/02 2.22 (1.84, 2.67) < 0.001
*Reporting changed from UK calendar to financial year to adhere to 
new national requirements.
Ref is the reference category.
Other variables entered into the analysis which were not significant 
were sex (P = 0.93) and new to treatment/previous treatment contact 
(P = 0.55).
Hosmer and Lemeshow Goodness-of-Fit Test: X2 = 8.102, P = 0.231.
Table 1: Comparisons between those discharged drug free and who dropped out at each year's end by age group, sex and previous 
treatment contact
Year of treatment outcome
1998 1999 2000/01* 2001/02
Discharged 
drug free
Dropped 
out
Discharged 
drug free
Dropped 
out
Discharged 
drug free
Dropped 
out
Discharged 
drug free
Dropped 
out
n (%) 443 (44.6%) 550 (55.4%) 718 (59.4%) 491 (40.6%) 360 (34.7%) 676 (65.3%) 281 (26.7%) 772 (73.3%)
< 25 years old 118 (26.6%) 166 (30.2%) 144 (20.1%) 110 (22.4%) 72 (20.0%) 114 (16.9%) 41 (14.6%) 146 (18.9%)
25 years old and over 325 (73.4%) 384 (69.8%) 574 (79.9%) 381 (77.6%) 288 (80.0%) 562 (83.1%) 240 (85.4%) 626 (81.1%)
within year comparison P = 0.219 P = 0.325 P = 0.210 P = 0.105
Female 130 (29.3%) 153 (27.8%) 227 (31.6%) 148 (30.1%) 109 (30.3%) 232 (34.3%) 92 (32.7%) 226 (29.3%)
Male 313 (70.7%) 397 (72.2%) 491 (68.4%) 343 (69.9%) 251 (69.7%) 444 (65.7%) 189 (67.3%) 546 (70.7%)
within year comparison P = 0.596 P = 0.587 P = 0.187 P = 0.279
New to treatment that year 239 (54.0%) 328 (59.6%) 324 (45.1%) 195 (39.7%) 193 (53.6%) 377 (55.8%) 118 (42.0%) 366 (47.4%)
Previously seen** 204 (46.0%) 222 (40.4%) 394 (54.9%) 296 (60.3%) 167 (46.4%) 299 (44.2%) 163 (58.0%) 406 (52.6%)
within year comparison P = 0.072 P = 0.062 P = 0.506 P = 0.119
*Reporting changed from UK calendar to financial year to adhere to new national requirements.
**Previously seen is defined as having had at least one prior treatment contact between 1997 and the year analysed.
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treatment disengagement, for those discharged drug free
compared to those who dropped out of treatment.
From 1999 and onwards, those referred into treatment via
the criminal justice system were significantly more likely
to drop out of treatment (and conversely significantly less
likely to be discharged drug free) than those who were
referred through other routes (Table 4). This difference
was evident for both all treatment episodes, and treatment
episodes of people who had not been recorded in treat-
ment the previous year.
Discussion
Investing in treatment provision is sound public health
policy, with psychosocial interventions and pharmaco-
therapy a cost-effective alternative to non-treatment or
imprisonment [21]. In the UK, treatment contact posi-
tively impacts on both health and criminal activity [22]
being associated with lower levels of drug use [23], reduc-
tions in injecting, improvements in psychological health,
a lower risk of non-fatal overdose [24] and lower levels of
drug related crime [25]. Increasing the proportion of indi-
viduals in treatment is therefore considered to be an
essential measure to tackle problematic drug use. In this
respect, measures initiated in the UK to increase the capac-
ity and availability of drug treatment in England, have
been very effective, with the number of people treated in
Cheshire and Merseyside rising 52% from 7594 in 1998
to 11,530 in 2004/05 (data not shown). Changes occur-
ring in this region have been mirrored in England as a
whole with numbers in treatment increasing 89% during
the same period [13]. This has been achieved in part by
increasing the drug treatment workforce, and conse-
quently treatment places, a policy promoted by the
National Treatment Agency for Substance Misuse follow-
ing its inception in 2001. Thus, 6794 drug treatment
workers were in post nationally in March 2002 compared
to 10,106 in September 2005 [26]. However, the quantity
of individuals in treatment is only one measure of success
and needs to be contextualised with intelligence relating
Cumulative re-presentation rates following drug free discharge (a) and drop out (b) from structured drug treatment serviceFigure 1
Cumulative re-presentation rates following drug free discharge (a) and drop out (b) from structured drug 
treatment service. Individuals presenting in each year of monitoring form each of the cohorts. Those discharged drug free 
(a) or dropping out (b) contribute to the cumulative re-presentation percentage in the first year they are seen again after leav-
ing services. If they then leave services again they become part of a second cohort of discharge or drop out.
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to treatment retention and the outcomes of individuals
leaving treatment services. Recent national figures suggest
that many drug users drop out long before treatment is
complete, with 34% dropping out before significant ben-
efits can accrue (suggested to be 12 weeks) [27].
Prospective cohort studies to examine outcomes are
costly, time consuming and are plagued with incomplete
follow up. The UK National Treatment Outcome Study
(NTORS) for example, was able to follow-up 72% of its
initial cohort after one year [23] and follow-up becomes
increasingly problematic over longer periods of time. Use
of routinely collected monitoring data from well-estab-
lished systems provides an alternative means by which
longer term outcomes may be assessed. It is possible, in
studies of this kind that variability across years is due to
the longitudinal nature of the study. However, whilst
treatment outcomes have been added/removed over the
years, definitions for 'drug free discharge' and 'drop out'
have remained stable. Using such systems, our results sug-
gest that increases in the numbers entering treatment are
at least temporally related to increased proportions drop-
ping out of services (7.2% in 1998 compared to 9.6% in
2001/02, P < 0.001). Conversely, there has been a trend
for a decreasing proportion of people discharged drug free
within the same time frame. In Cheshire and Merseyside,
5.8% of treatment clients had an end of year outcome of
discharged drug free in 1998 compared to 3.5% in 2001/
02 (P < 0.001). On closer examination, these increasing
(drop out) and decreasing (drug free discharge) trends are
only evident from 1999 onwards. 1999 saw a reduction in
the number of drug users in treatment, a corresponding
rise in the proportion who were discharged drug free and
a fall in the proportion who dropped out. Additionally, as
criminal justice based schemes were initiated in 2000, the
role of the criminal justice system on treatment outcomes
cannot be ignored. In 2000 onwards, the proportion of
people discharged drug free at the end of the year
decreased, whilst the proportion dropping out showed
the opposite trend. Additionally our results show that, in
1999 onwards, those referred into treatment via a criminal
justice source were significantly more likely to drop out of
treatment and significantly less likely to be discharged
drug free than their counterparts referred from other
sources (see Table 4).
By definition, coercive strategies, criminal justice based or
otherwise, force people into treatment when they are not
ready to contemplate changing their drug using behav-
iour. Theoretically, those coerced into treatment during
the 'pre-contemplation' stage of the Transtheoretical
Model of behaviour change are intuitively expected to fair
less well in treatment than those at the 'preparation' or
'action' stage who voluntarily self refer [28]. Additionally,
whilst external motivation (e.g. the promise of bail rather
than a custodial sentence) seems to promote short-term
abstinence from alcohol and other drugs, internal motiva-
tion appears to be better for longer-term success. Once in
treatment, practitioners therefore face the challenge of
shifting a drug user's motivation from external to internal
incentives [29]. If measures to increase uptake become
more coercive [11] treatment must be flexible to adapt to
drug users who may be very different from ones who vol-
untarily seek assistance. In-patient care, for example, does
not have to be solely for the purpose of detoxification and
drop out may be reduced if short in-patient stays were
used at the beginning of treatment to identify the opti-
mum dose of prescribed drugs [30]. Few in-patient serv-
ices offer interventions for stimulant users but this group
are often disproportionately represented in those
recruited though criminal justice mechanisms, and may
benefit considerably from such interventions [30].
It is important to note the possibility that a person's pre-
ferred main drug may be confounding the observed rela-
tionship between referral source and treatment outcome if
criminal justice referrals disproportionately consist of
stimulant users (particularly crack users). No proven effec-
tive pharmacological substitute exists for stimulant users
as methadone exists for opiate addiction and stimulant
services are in relative infancy. Less satisfactory treatment
outcomes for UK methadone patients who are concurrent
Table 3: Factors predicting re-presentation to treatment for 
those who dropped out and were discharged drug free in the 
previous year
Factors predicting re-presentation as treatment (N = 4291)
Variable Adjusted odds ratio (95% 
confidence interval)
P value
Age group 0.031
10 to 19 Ref
20 to 29 1.87 (1.27, 2.75) 0.002
30 to 39 1.73 (1.17, 2.55) 0.006
40 to 49 1.50 (0.95, 2.38) 0.081
50 to 59 1.38 (0.71, 2.71) 0.345
60 to 69 1.72 (0.15, 20.36) 0.667
Year < 0.001
1998 Ref
1999 1.17 (0.96, 1.42) 0.117
2000/01* 1.28 (1.04, 1.56) 0.017
2001/02 2.60 (2.14, 3.15) < 0.001
Treatment history
New to treatment Ref
Prior treatment contact 2.50 (2.18, 2.86) < 0.001
*Reporting changed from UK calendar to financial year to adhere to 
new national requirements.
Ref is the reference category.
Other variables entered into the analysis which were not significant 
were sex (P = 0.395) and outcome (drop out versus discharged drug 
free) (P = 0.522).
Hosmer and Lemeshow Goodness-of-Fit Test: X2 = 7.273, P = 0.508.
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stimulant users has been previously suggested [31]. Two
other factors are worthy of note. Firstly, population stud-
ies show that cocaine and crack cocaine use has risen in
the UK since 1998 [32] and may have impacted on treat-
ment outcomes. Secondly, opioid treatment is generally
longer than treatment for stimulant addiction so, as drop
out is more common than drug free discharge, it could be
argued that stimulant users (referred preferentially
through the criminal justice system) have greater opportu-
nity to drop out than their non-stimulant using counter-
parts. However here we consider end of year treatment
outcomes relating to the treatment system rather than
individual treatment episodes (unless stated) with opioid
and stimulant users having equal opportunity to be in
contact with the system at each years' end.
Rates of re-presentation to drug services for those who
dropped out of treatment and those discharged drug free
have significantly increased between 1998 and 2001/02.
For example, across Cheshire and Merseyside, the propor-
tion re-presenting to treatment the year following drug
free discharge increased from 27.8% for those discharged
in 1998, compared to 44.5% for those discharged in
2001/02 (P < 0.001). Similarly, rates of re-presentation in
the year following drop out increased from 22.9% for
those dropping out in 1998 to 48.6% for those dropping
out in 2001/02 (P < 0.001) (see Figure 1 for cumulative
rates of re-presentation). These increases in the rate at
which those leaving service re-present in subsequent years
is a likely result of a combination of factors already dis-
cussed. Importantly, investing in treatment provision has
considerably reduced treatment waiting times. Average
waiting times have, for example halved between Decem-
ber 2001 and October 2004 in all treatment modalities
except services focusing on abstinence or stabilisation for
those with a high level of need (primarily detoxification
services; tier 4 provision) [30]. People voluntarily seeking
treatment have, therefore, found it easier to access services
when motivation is high rather than wait until a place
becomes available. Similarly, places have been available
for those entering treatment via the criminal justice sys-
tem. However, we also show that completion of treatment
does not protect people from future drug use with rates of
re-presentation being similar for those that drop out of
treatment and those discharged drug free. This raises
issues about the appropriateness of aftercare provision.
Such services should be examined to ensure that they are
seen as an integral part of the whole integrated care path-
way [17], and what further measures can be taken to
engage individuals who have achieved abstinence in such
services. Whilst rates of relapse have been shown to be
delayed for those attending aftercare services [33], treat-
ment modalities which encourage drug free discharge, pri-
marily in-patient detoxification facilities, must be better
integrated with such services and interventions including
community housing, training and support on offer [30].
Encouraging young people to engage with treatment serv-
ices is a well-recognised problem [14] but reducing the
time between drug initiation and treatment engagement
Table 4: Episodic drug treatment outcome (discharged drug free and drop out) by referral source
Year of 
treatment 
outcome
Referral source Outcome of treatment episode
All episodes Episodes for people not in treatment the previous year
Discharged drug free Dropped out Discharged drug free Dropped out
N % N % N % N %
1998 Criminal Justice 11 30.6 25 69.4 -- -- -- --
Non-Criminal Justice 292 43.5 380 56.5 -- -- -- --
Within year comparison P = 0.128 --
1999 Criminal Justice 33 37.5 55 62.5 16 27.6 42 72.4
Non-Criminal Justice 444 59.6 301 40.4 172 66.7 86 33.3
Within year comparison P < 0.001 P < 0.001
2000/01* Criminal Justice 20 15.5 109 84.5 11 12.9 74 87.1
Non-Criminal Justice 272 41.9 377 58.1 142 40.5 209 59.5
Within year comparison P < 0.001 P < 0.001
2001/02 Criminal Justice 25 14.0 153 86.0 18 15.1 101 84.9
Non-Criminal Justice 335 30.9 749 69.1 167 28.7 414 71.3
Within year comparison P < 0.001 P = 0.002
*Reporting changed from UK calendar to financial year to adhere to new national requirements.
1998 was the first year of analysis. It is therefore not possible to differentiate between 'all episodes' and 'episodes for people not in treatment the 
previous year' for this annual cohort.
BMC Public Health 2006, 6:205 http://www.biomedcentral.com/1471-2458/6/205
Page 8 of 9
(page number not for citation purposes)
has been recognised as important, particularly for users of
more problematic drugs. Whilst a progression from abuse
to dependence generally occurs over time in users of alco-
hol and cannabis, for cocaine and opiate users, abuse and
dependence disorders tend to occur in the same year so
timely intervention is essential before dependence devel-
ops [34]. Here we show that younger age predicted drop
out from treatment and those in the older age groups were
more likely than their younger counterparts to re-present
at treatment. Current measures targeting young people
therefore need particular consideration. Services estab-
lished for traditional dependent opiate users may be
unsuitable for some young people who are frequently
users of stimulants and who perceive themselves to be
drug users rather than drug dependents [34].
Drop out and relapse may be an inevitability among some
client groups and in particular those who have been
coerced into treatment. However if treatment is viewed
from a chronic care perspective, with drug users often
requiring many cycles of treatment [35], timely re-engage-
ment becomes important to ensure that gains from previ-
ous periods of treatment are not lost. To some extent this
seems to have progressed with increasing rates of re-pres-
entation for those discharged drug free and those drop-
ping out being observed. Re-engagement may be further
improved by establishing strong linkages between struc-
tured treatment and low threshold services such as syringe
exchange schemes and through effective information
exchange between agencies as drug users leave one service
and reappear shortly afterwards in another.
Conclusion
In England, since 1998, huge fiscal investment in struc-
tured drug treatment provision has expanded the work-
force, reduced waiting times and consequently swelled the
number of problematic drug users accessing services. Such
strategies have speeded up the rate at which those leaving
services (following drug free discharge or drop out) re-
present for a further period of treatment. Whilst drop out
has always been an inevitability among this client group,
we show that, in Cheshire and Merseyside, the proportion
dropping out of treatment annually has also significantly
increased, highlighting difficulties in retaining people in
treatment. Consequently a smaller proportion of drug
users are being discharged drug free. In particular, those
referred via the criminal justice system are significantly
more likely to drop out of treatment than those referred
through non-criminal justice routes. Additionally, we
show that treatment completion does not protect against
further drug use, with rates of re-presentation for those
discharged drug free being similar to those who dropped
out of treatment suggesting that aftercare services need
further consideration. Better outcomes and decreased sub-
stance use is associated with longer periods of treatment
[36,37] and, if drug use is viewed as a chronic condition,
treatment retention is arguably more important than drug
free discharge, especially if discharge only results in
relapse and further periods of chaotic drug use with asso-
ciated risks. We also show that, for those leaving services,
those with prior treatment history were more than twice
as likely to re-present for further treatment the following
year than those who were treatment naïve, suggesting that
many are not overly disenchanted with the treatment they
received or unwilling to try again. Measures to facilitate
timely re-entry into the treatment system are important.
We conclude that recent measures to increase drug treat-
ment participation have speeded up a revolving door both
into and out of treatment. The effectiveness of aftercare
services for those leaving treatment drug free and the
impact of coercive measures to facilitate treatment engage-
ment on longer-term outcomes, in particular retention,
need further consideration.
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